Alnylam Pharmaceuticals' Cash from Investing Activities rose 1756.55% to $501.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $420.6 million, marking a year-over-year increase of 238.08%. This contributed to the annual value of -$116.8 million for FY2024, which is 65.26% up from last year.
As of FY2024, Alnylam Pharmaceuticals' Cash from Investing Activities stood at -$116.8 million, which was up 65.26% from -$336.4 million recorded in FY2023.
In the past 5 years, Alnylam Pharmaceuticals' Cash from Investing Activities ranged from a high of $169.4 million in FY2022 and a low of -$435.5 million during FY2020.
Moreover, its 3-year median value for Cash from Investing Activities was -$116.8 million (2024), whereas its average is -$94.6 million.
Per our database at Business Quant, Alnylam Pharmaceuticals' Cash from Investing Activities skyrocketed by 161.97% in 2022 and then slumped by 298.61% in 2023.
Over the past 5 years, Alnylam Pharmaceuticals' Cash from Investing Activities (Yearly) stood at -$435.5 million in 2020, then soared by 37.25% to -$273.3 million in 2021, then skyrocketed by 161.97% to $169.4 million in 2022, then tumbled by 298.61% to -$336.4 million in 2023, then skyrocketed by 65.26% to -$116.8 million in 2024.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value